摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(2,4,6-三羟基-3,5-二甲基苯基)乙酮 | 13383-63-6

中文名称
1-(2,4,6-三羟基-3,5-二甲基苯基)乙酮
中文别名
2,4,6-三羟基-3,5-二甲基苯乙酮;1-(2,4,6-三羟基-3,5-二甲基苯基)乙酮;2,4,6-三羟基-3,5-二甲基苯乙酮
英文名称
1-(2,4,6-trihydroxy-3,5-dimethylphenyl)ethan-1-one
英文别名
1-(2,4,6-Trihydroxy-3,5-dimethylphenyl)ethanone;1-(2,4,6-trihydroxy-3,5-dimethyl-phenyl)-ethanone;1-(2,4,6-Trihydroxy-3,5-dimethyl-phenyl)-aethanon;2,4,6-trihydroxy-3,5-dimethylacetophenone;3,5-Dimethyl-phloroacetophenon;Dimethylphloroacetophenon
1-(2,4,6-三羟基-3,5-二甲基苯基)乙酮化学式
CAS
13383-63-6
化学式
C10H12O4
mdl
——
分子量
196.203
InChiKey
GIMGGNBXMNVHHR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    220-222 °C
  • 沸点:
    355.5±37.0 °C(Predicted)
  • 密度:
    1.318±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    77.8
  • 氢给体数:
    3
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2914400090

SDS

SDS:1004c04f71dc0c1e5beb71e969f5512d
查看

制备方法与用途

化学性质:结晶,熔点高于220℃。

用途:作为杜鹃素的中间体。

生产方法:将1,3,5-三羟基-2,4-二甲基苯与乙腈在氯化锌的参与下进行加成反应,生成2-亚氨基乙基化合物,随后水解制得所需产品。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(2,4,6-三羟基-3,5-二甲基苯基)乙酮甲醇氧气 、 lead acetate 作用下, 生成 4-乙酰基-2-羟基-2,6-二甲基-环己烷-1,3,5-三酮
    参考文献:
    名称:
    The Synthesis and Absorption Spectra of Some Analogs of Humulon1
    摘要:
    DOI:
    10.1021/ja01148a511
  • 作为产物:
    描述:
    2,4,6-三乙酰氧基-1,3-二甲基苯boron trifluoride diacetate 作用下, 反应 0.25h, 以40%的产率得到1-(2,4,6-三羟基-3,5-二甲基苯基)乙酮
    参考文献:
    名称:
    Hauteville, Marcelle; Stomberg, Rolf; Gaillard, Pascale, Liebigs Annalen, 1995, # 9, p. 1707 - 1710
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Pharmaceutical compositions containing compounds with a flavanone
    申请人:Inverni Della Beffa S.p.A.
    公开号:US04636569A1
    公开(公告)日:1987-01-13
    Compounds with a flavanone skeleton having the formula I ##STR1## in which R.sub.1 and R.sub.2, which may be the same or different, represent hydrogen, hydroxyl, methoxyl, thiomethyl, amino or substituted amino, are endowed with expectorant, mucolytic, mucopoietic, choleretic and hypolipaemia-producing activity.
    具有公式I的黄酮骨架化合物,其中R1和R2表示氢、羟基、甲氧基、硫代甲基、氨基或取代氨基,它们具有祛痰、液化痰液、刺激粘膜细胞增生、促进胆汁分泌和降低血脂的活性。
  • Pharmaceutical compositions containing compounds with a flavanone skeleton and process for the preparation of said compounds
    申请人:INVERNI DELLA BEFFA S.P.A.
    公开号:EP0122053A2
    公开(公告)日:1984-10-17
    Compounds with a flavanone skeleton having the formula I in which R1 and R2, which may be the same or different, represent hydrogen, hydroxyl, methoxyl, thiomethyl, amino or substituted amino, are endowed with expectorant, mucolytic, mucopoietic, chloretic and hypolipaemia-producing activity.
    具有式 I 的黄烷酮骨架的化合物,其中 R1 和 R2(可以相同或不同)代表氢、羟基、甲氧基、硫甲基、氨基或取代氨基,具有祛痰、粘液溶解、粘液造血、软化胆囊和降血脂活性。
  • 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY
    申请人:Xiamen Sinopeg Biotech Co., Ltd.
    公开号:EP3315531A1
    公开(公告)日:2018-05-02
    Disclosed are an 8-arm polyethylene glycol (PEG) derivative (formula 1), manufacturing method and modified bio-related substance thereby, wherein a tetravalent group U and four trivalent groups Ec form a highly symmetric octavalent central structure CORE0 together, Lc connects the octavalent center to eight PEG arms having polydiversity or monodiversity and having n1-n8 as the degrees of polymerization thereof. The terminal of one PEG chain is connected to at least one functional group F (k ≥ 1), and said PEG chain and F can be directly connected (g = 0) or connected with a divalent linking group L0 connected with a terminal branched group G (g = 1) therebetween. The latter provides more reacting sites to combine more pharmaceutical molecules, thereby increasing the drug loading capacity. The near-center symmetric structure of the derivative allows more precise control over the molecular weight during large-scale production, thereby facilitating acquisition of a product having a narrower molecular weight distribution. A bio-related substance modified thereby has a more uniform and controllable performance.
    本发明公开了一种 8 臂聚乙二醇(PEG)衍生物(式 1)、其制造方法和改性生物相关物质,其中一个四价基团 U 和四个三价基团 Ec 共同形成一个高度对称的八价中心结构 CORE0,Lc 将八价中心连接到八个 PEG 臂上,这些 PEG 臂具有多元性或单元性,其聚合度为 n1-n8。一条 PEG 链的末端与至少一个官能团 F(k ≥ 1)相连,所述 PEG 链和 F 可以直接相连(g = 0),也可以通过二价连接基 L0 与中间的末端支化基 G(g = 1)相连。后者提供了更多的反应位点,可以结合更多的药物分子,从而提高药物负载能力。衍生物的近中心对称结构可以在大规模生产过程中更精确地控制分子量,从而有利于获得分子量分布更窄的产品。由此改性的生物相关物质具有更均匀、更可控的性能。
  • Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof
    申请人:XIAMEN SINOPEG BIOTECH CO., LTD.
    公开号:US10434182B2
    公开(公告)日:2019-10-08
    Disclosed are an eight-arm polyethylene glycol (PEG) derivative (formula I), production method therefor and modified bio-related substance thereby. Wherein, one tetravalent group U together with four trivalent groups Ec form a highly symmetrical octavalent group CORE0; Lc connects the octavalent group to eight PEG chains having polydispersity or monodispersity and having n1 to n8 as the degree of polymerization thereof; the terminal of one PEG chain is connected to at least one functional group F (k≥1); said PEG chain and F therebetween can be directly connected (g=0) or be indirectly connected via a linking group L0 to a terminal end-branching group G (g=1); the latter provides more reactive sites for binding more drug molecules and increases the drug loading. The eight-arm polyethylene glycol derivative has a centrosymmetric or approximately centrosymmetric structure, and leads to more precise control of the molecular weight in large-scale production and much narrower distribution of molecular weight for products. The modified bio-related substance thereby has a more uniform and controllable performance.
    本发明公开了一种八臂聚乙二醇(PEG)衍生物(式 I)、其生产方法及其改性生物相关物质。其中,一个四价基团 U 与四个三价基团 Ec 形成一个高度对称的八价基团 CORE0;Lc 将八价基团连接到八条具有多分散性或单分散性且聚合度为 n1 至 n8 的 PEG 链上;一条 PEG 链的末端与至少一个官能团 F 连接(k≥1);所述 PEG 链和 F 之间可以直接连接(g=0),也可以通过连接基团 L0 与末端支化基团 G 间接连接(g=1);后者提供了更多的反应位点,可以结合更多的药物分子,增加药物负载量。八臂聚乙二醇衍生物具有中心对称或近似中心对称结构,因此在大规模生产中可以更精确地控制分子量,产品的分子量分布也更窄。因此,改性生物相关物质的性能更均匀、更可控。
  • Riedl; Huebner, Chemische Berichte, 1957, vol. 90, p. 2870,2875
    作者:Riedl、Huebner
    DOI:——
    日期:——
查看更多